Available data obtained in BC syngeneic mouse models showed that the RT-induced antitumor immunity required a combination with drugs able to counteract immunosuppressive factors (as CTLA4, TGF-β, and PD-1/PD-L1) to improve tumor control by radiation and definitively favor abscopal responses (55–57). The gene discussed is TGFB1; the disease is breast cancer.